Patents by Inventor Jean-Pierre Gorvel

Jean-Pierre Gorvel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CULTURED MYELOID DENDRITIC CELLS ISOLATED FROM PEYERS PATCHES AND USES THEREOF
    Publication number: 20150196634
    Abstract: Cultured lysozyme-secreting myeloid dendritic cells isolated from the subepithelial dome of Peyer's patches in the small intestine are provided. The myeloid dendritic cells are used in screening methods to identify agents which interact with myeloid dendritic cells, for example, antigens, allergens, antimicrobial agents, or agents that modulate the activity of myeloid dendritic cells. The cells are also used to identify agents which bind to and/or are taken up by myeloid dendritic cells, and which can act as delivery vehicles for delivering substances of interest to myeloid dendritic cells in vivo.
    Type: Application
    Filed: March 25, 2015
    Publication date: July 16, 2015
    Inventors: Jean-Pierre GORVEL, Hugues LELOUARD
  • Immunoadjuvant compounds and uses thereof
    Patent number: 9061066
    Abstract: Cyclic beta glucan compounds function as an immunoadjuvant when administered prior to, concommitantly with, or subsequent to the administration of one or more antigens to a subject. These adjuvant compounds may be effectively used as dendritic cell activating molecules.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: June 23, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.), Universite d'Aix-Marseille
    Inventors: Jean-Pierre Gorvel, Jacques Banchereau, Anna Martirosyan, Eynav Klechevsky, Sangkon Oh
  • Modified gram-negative bacteria for use as vaccines
    Patent number: 9034630
    Abstract: The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: May 19, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique—CNRS, Université d'Aix Marseille, UNIVERSIDAD DE NAVARRA
    Inventors: Jean-Pierre Gorvel, Vilma Arce Gorvel, Maite Iriarte, Ignacio Moriyon, Raquel Conde-Alvarez
  • Modified Gram-Negative Bacteria For Use As Vaccines
    Publication number: 20140286996
    Abstract: The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host.
    Type: Application
    Filed: June 5, 2014
    Publication date: September 25, 2014
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique - CNRS, Universite de la Mediterranee - Aix-Marseille II, Universidad de Navarra
    Inventors: Jean-Pierre Gorvel, Vilma Arce Gorvel, Maite Iriarte, Ignacio Moriyon, Raquel Conde-Alvarez
  • Modified gram-negative bacteria for use as vaccines
    Patent number: 8778655
    Abstract: The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: July 15, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique—CNRS, Universite de la Mediterranee—Aix-Marseille II, Universidad de Navarra
    Inventors: Jean-Pierre Gorvel, Vilma Arce Gorvel, Maite Iriarte, Ignacio Moriyon, Raquel Conde-Alvarez
  • NOVEL IMMUNOADJUVANT COMPOUNDS AND USES THEREOF
    Publication number: 20130129756
    Abstract: The present invention relates to a cyclic beta glucan compound for use as an immuno adjuvant and vaccine composition comprising thereof. These novel adjuvant compounds represent in particular a new class of dendritic cell activating molecules.
    Type: Application
    Filed: June 6, 2011
    Publication date: May 23, 2013
    Inventors: Jean-Pierre Gorvel, Jacques Banchereau, Anna Martirosyan, Eynav Klechevsky, Sangkon Oh
  • MODIFIED GRAM-NEGATIVE BACTERIA FOR USE AS VACCINES
    Publication number: 20120183576
    Abstract: The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host.
    Type: Application
    Filed: September 21, 2010
    Publication date: July 19, 2012
    Inventors: Jean-Pierre Gorvel, Vilma Arce Gorvel, Maite Iriarte, Ignacio Moriyon, Raquel Conde-Alvarez